Overview
- The Lancet-published MASAI trial involving more than 100,000 women found 12% fewer interval cancers and 16% fewer invasive interval cancers with AI-supported screening versus the standard two-radiologist approach.
- The AI workflow triaged low-risk exams to a single reader and increased the share of cancers detected during screening to 81% compared with 74% in the control arm.
- Trial analyses report about a 44% reduction in radiologist screen-reading workload without lowering cancer detection rates.
- Clinicians and charities call the approach a major advance that can help flag smaller, earlier-stage tumors, with some expecting hospital use relatively soon.
- Evidence leaders caution that broader, multi-center validation, monitoring for missed cancers, and cost-effectiveness studies are needed, and a survey indicates most patients still prefer a radiologist to review images.